I apologize for not answering your question earlier, but that is a tough question to answer, as there are many variables involved. The figure is based on risk-adjusted projected net cash flows, and those numbers are not easy to pin down. Nader said at one point that CV could be responsible for $8 B in 2021, but we would get a royalty, not the whole $8 B. On top of that what about the years beyond that, including additional markets? We have similar numbers projected for HIV, but again, those are gross numbers not our revenues, and the same unknowns considering potentially additional markets. Additionally, there may be upwards of 50+ potential indications, but who knows which ones, if any, will play out, and how long (how much $) they will take to develop. As we sit here, today, we sit with a market cap of $1.7 B. Nader has said that he wouldn't sell out for less than $100/share, which suggests a market cap of around $55 B. A couple of weeks ago, on one of his videos he stated that he thought that we should be trading at $25/$30 per share right now, and he has access to the numbers used to calculate those figures. With that said, it is not like Nader to exaggerate to make a point, is it? (LOL) So at the end of the day, I am giving you a long-winded answer without answering your question. Well, since it is pretty obvious that Nader controls the BOD, lets go by his numbers, and add a premium for potential "blue sky" of additional indications (no guarantee, but have promise based on mechanism of action) of an additional 25% on top of what Nader believes that the pps should be now. Considering the activities of late, many investors would probably settle for the "quick nickle over the slow dime," and take a helluva lot less. I may be among them. Clear as mud?